Vyzulta (soln)

Vyzulta (soln)

Generic: Latanoprostene bunod 0.024%

Vyzulta (soln)
DOSAGE 1 gtt QPM
GENERIC Latanoprostene bunod 0.024%
SIZE 2.5 mL, 5 mL
INDICATIONS Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
MECHANISM OF ACTION Increasing aqueous outflow
MICROBIOLOGY prostaglandin / nitric oxide (NO)-donor | Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
CONTRAINDICATIONS & WARNINGS Increase in pigmentation of the iris and periorbital tissues, increase in length of eyelashes, intraocular inflammation, macular edema. Contact lenses should be removed 15 minutes prior to instillation of Vyzulta
PEDIATRIC USE Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
PREGNANCY There are no available human data for the use of VYZULTA during pregnancy to inform any drug associated risks.
NOTE